Selected articles

Articles for label Jurečková Andrea are displayed.. Show all articles

Medullary thyroid carcinoma – case reports

05/2021 MUDr. Andrea Jurečková
Two case reports of patients with metastatic medullary thyroid carcinoma treated with tyrosine kinase inhibitors as a 1st line treatment are presented. The effectiveness of the treatment is compared - long-term treatment response in patient with early detected metastatic disease versus quick progression in patient with late diagnosis of advanced carcinoma and large proportion of metastatic lesions.
ENTIRE ARTICLE

Neuroendocrine carcinoma of the liver – case report

06/2020 MUDr. Andrea Jurečková
A case report of a patient with neuroendocrine carcinoma of the liver with hormonal symptomatology is presented. Despite the massive initial involvement of the liver and non-effective 1st line platinum-based treatment, the patient was eventually treated with three subsequent lines of palliative chemotherapy and survived more than 2,5 years.
ENTIRE ARTICLE

Lenvatinib as a new possibility of treatment of thyroid gland carcinoma

05/2017 MUDr. Andrea Jurečková
Malignant tumours of the thyroid gland are relatively rare, their incidence is, however, permanently escalating. The most frequent among them is the differentiated thyroid cancer: papillary, follicular and Hurthle cell carcinomas. In the initial stages the prognosis of these tumours is excellent. Nevertheless, only few therapeutic modalities are available for advanced or metastatic disease. In the last decade, a better understanding of the molecular events involved in the thyroid cancer has led to introduction of new targeted agents for the management of advanced radioiodine-refractory disease. Multikinase inhibitors are able to block pathways involved in the proliferation, invasion, and neoangiogenesis of thyroid cancer. Their effectiveness was proved in several clinical placebo-controlled clinical trials. The purpose of this paper is a special focus on lenvatinib, a multikinase inhibitor.
ENTIRE ARTICLE